KEY TAKEAWAYS
- The PROAK study analyzed clinician and patient satisfaction with tirbanibulin to determine its potential as a future AK treatment.
- In the study, adult pts with AKs on the face or scalp were treated with tirbanibulin 1% ointment for a 5-day course as part of their usual care.
- Clinician and patient satisfaction with tirbanibulin was high, which suggest that tirbanibulin is a viable option in treating AK lesions.
In this single-arm, prospective cohort study, adult patients with AKs on the face or scalp were treated with tirbanibulin 1% ointment for a 5-day course as part of their usual care. The study included surveys and clinical assessments completed by patients and clinicians at baseline, Week-8 (timeframe for primary endpoints), and Week-24. Patients (pts) and clinicians completed Treatment Satisfaction Questionnaire for Medication (TSQM-9) surveys in Week-8 containing 3 domains: treatment effectiveness, convenience of use, and global satisfaction with treatment. At Week-8, patients and clinicians expressed a high likelihood of considering tirbanibulin for future AK treatment.
According to the study, 290 pts with AK completed the assessments at Week-8. The pts had a mean age of 66.3 years, with 31.4% being female. Most pts, 61.7%, had a history of skin cancer. In terms of Fitzpatrick skin type, 7.6% were type I, 71.4% were type II, 18.6% were type III, 1.4% were type IV, and 1.0% were type V. At baseline, the patients self-reported their skin-texture as 39.7% dry, 47.6% smooth, 19.7% rough, 18.6% bumpy, 35.2% scaly, and 6.6% blistering/peeling. The results of the tirbanibulin treatment looked promising, as patients and clinicians at W8 were highly satisfied with it across all three domains of TSQM-9. Moreover, there is a remarkably high likelihood of considering tirbanibulin treatment in the future should the need arise.
The satisfaction levels of both clinicians and patients with the tirbanibulin treatment were high. After completing the 5-day course at Week-8, both parties expressed a strong desire to opt for this treatment in the future. The feedback establishes tirbanibulin as a viable option for treating AK lesions.
Source: https://eado2023.com/wp-content/uploads/2023/04/Abstract-Band_EADO2023_Stand-21-04-2023-kl.pdf
Clinical Trial: https://classic.clinicaltrials.gov/ct2/show/NCT05260073
Todd Schlesinger1, James Del Rosso2, Dr Vishal A. Patel3, Leon Kircik4,5, April Armstrong6, Brian Berman7, Neal Bhatia8, Mark Lebwohl4, Darrell Rigel4, Dr Siva Narayanan9, Volker Koscielny10, Merce Hereu Planellas10 1 Clinical Research Center of the Carolinas, Charleston, USA / 2 JDr Dermatology Research/Thomas Dermatology, Las Vegas, USA / 3 George Washington School of Medicine and Health Sciences, Washington, USA / 4 Icahn School of Medicine at Mount Sinai, New York, USA / 5 Skin Sciences, PLLC, Louisville, USA / 6Keck School of Medicine, University of Southern California, Los Angeles, USA / 7University of Miami Miller School of Medicine, Miami, USA / 8 Therapeutics Clinical Research, San Diego, USA / 9 Avant Health LLC, Bethesda, USA / 10 Almirall SA, Barcelona, Spain
